BLS M22
Alternative Names: BLS-M22Latest Information Update: 28 Jul 2022
At a glance
- Originator Bioleaders Corporation
- Class Bacteria; Gene therapies; Immunotherapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in South Korea (PO, Capsule)
- 04 Jan 2019 BioLeaders plans a phase I trial for Duchenne muscular dystrophy (In volunteers in South Korea (NCT03789734)
- 28 Nov 2018 Preclinical trials in Duchenne muscular dystrophy in South Korea (PO) prior to November 2018